OPKO Health (NASDAQ:OPK) Director Robert Scott Fishel acquired 10,000 shares of OPKO Health stock in a transaction on Friday, April 13th. The shares were purchased at an average cost of $3.02 per share, for a total transaction of $30,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of OPKO Health stock opened at $2.99 on Monday. The firm has a market cap of $1,672.83, a price-to-earnings ratio of -10.31 and a beta of 1.56. OPKO Health has a 52 week low of $2.66 and a 52 week high of $7.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.14 and a quick ratio of 0.98.
OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, March 1st. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The business had revenue of $193.70 million for the quarter, compared to the consensus estimate of $307.44 million. OPKO Health had a negative net margin of 28.93% and a negative return on equity of 7.87%. sell-side analysts forecast that OPKO Health will post -0.48 EPS for the current year.
Several analysts have commented on OPK shares. Cantor Fitzgerald set a $20.00 target price on shares of OPKO Health and gave the company a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. BidaskClub upgraded shares of OPKO Health from a “strong sell” rating to a “sell” rating in a research report on Friday, January 26th. ValuEngine cut shares of OPKO Health from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, JPMorgan Chase cut shares of OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price for the company. in a research report on Friday, March 2nd. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $11.29.
About OPKO Health
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.